Brought to you by

Bayer signs another ADC agreement with Seattle Genetics
07 Dec 2015
Executive Summary
In their second tie-up, Bayer HealthCare LLC has received options to globally license cancer biotech Seattle Genetics Inc.’s antibody-drug conjugate (ADCs) technology against multiple oncology targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com